Demo Data from VLDB 2026 / reviewers in the wild / expert
Antonio de Falco
dblp:301/4936
· DBLP profile ↗
1ranked-venue papers
1as first author
1since 2021 · last 2021
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% | |
| Artificial intelligence
1 paper |
Probabilistic and Bayesian machine learning · 100% |
Topics — the 3 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology
drug discovery |
0.5 | 1 | 2021 | Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targets · Bioinform. 2021 |
Bioinformatics and computational biology › drug discovery › target identification
drug target prioritization |
0.5 | 1 | 2021 | Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targets · Bioinform. 2021 |
Machine learning › Probabilistic and Bayesian machine learning › stochastic processes
gaussian process |
0.1 | 1 | 2021 | Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targets · Bioinform. 2021 |
Methods — techniques the papers use, named apart from their topics
positive-unlabeled learning · 1.0hyperparameter selection · 1.0gaussian process · 1.0
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2021 | Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targetsabstractMOTIVATION: The cost of drug development has dramatically increased in the last decades, with the number new drugs approved per billion US dollars spent on R&D halving every year or less. The selection and prioritization of targets is one the most influential decisions in drug discovery. Here we present a Gaussian Process model for the prioritization of drug targets cast as a problem of learning with only positive and unlabeled examples. RESULTS: Since the absence of negative samples does not allow standard methods for automatic selection of hyperparameters, we propose a novel approach for hyperparameter selection of the kernel in One Class Gaussian Processes. We compare our methods with state-of-the-art approaches on benchmark datasets and then show its application to druggability prediction of oncology drugs. Our score reaches an AUC 0.90 on a set of clinical trial targets starting from a small training set of 102 validated oncology targets. Our score recovers the majority of known drug targets and can be used to identify novel set of proteins as drug target candidates. AVAILABILITY AND IMPLEMENTATION: The matrix of features for each protein is available at: https://bit.ly/3iLgZTa. Source code implemented in Python is freely available for download at https://github.com/AntonioDeFalco/Adaptive-OCGP. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Antonio de Falco, Zoltán Dezsö, Francesco Ceccarelli, Luigi Cerulo, Angelo Ciaramella, Michele Ceccarelli |
Bioinform. | 1 |